Abstract

Borregaard AS will release quarterly results on July 16, 2026 before-market, and consensus points to marginal revenue growth and notably lower adjusted EPS as investors watch pricing, product mix, and cost pass-through dynamics into the second half.

Market Forecast

Consensus for the current quarter anticipates revenue of 1.99 billion Norwegian kroner, up 0.25% year over year, EBIT of 296.58 million Norwegian kroner, down 25.15% year over year, and adjusted EPS of 1.59, down 41.02% year over year. Forecasts for gross margin and net profit margin are not explicitly disclosed, but the mix of slightly lower EBIT on broadly stable revenue implies ongoing margin pressure versus the prior year. The main business is expected to emphasize disciplined pricing and product mix to support margins in the face of flat revenue momentum; execution on cost control and efficiency remains central to delivering EBIT in line with expectations. The most promising segment by potential swing factor is Fine Chemicals, which generated 220.00 million Norwegian kroner last quarter; year-over-year segment growth was not disclosed in available materials, but order phasing and delivery timing can introduce upside or downside versus consensus.

Last Quarter Review

Borregaard AS reported revenue of 2.01 billion Norwegian kroner, a gross profit margin of 21.35%, GAAP net profit attributable to the parent company of 182.00 million Norwegian kroner with a net profit margin of 9.08%, and adjusted EPS of 1.82, down 27.78% year over year; net profit increased 324.69% quarter over quarter. A key financial highlight was a modest top-line outperformance versus prior estimates alongside an EBIT shortfall, with revenue at 2.01 billion Norwegian kroner (a 32.00 million Norwegian kroner beat), EBIT at 276.00 million Norwegian kroner (an 85.50 million Norwegian kroner miss), and adjusted EPS 0.58 below expectations. From a business mix perspective, the last quarter’s revenue allocation was anchored by Bio Solutions at 1.07 billion Norwegian kroner, complemented by Bio Materials at 729.00 million Norwegian kroner and Fine Chemicals at 220.00 million Norwegian kroner, with a consolidation offset of -11.00 million Norwegian kroner; year-over-year variations by segment were not disclosed alongside the quarterly mix, making pricing and mix commentary more central to interpreting margin trends.

Current Quarter Outlook

Bio Solutions: pricing, mix, and volume alignment

Bio Solutions remains the revenue anchor, contributing 1.07 billion Norwegian kroner in the most recent quarter. With consensus projecting group revenue of 1.99 billion Norwegian kroner this quarter and EBIT of 296.58 million Norwegian kroner, the implied setup for Bio Solutions hinges on a combination of pricing discipline and mix optimization to protect margin while volumes track near steady. The last reported gross margin of 21.35% and net profit margin of 9.08% provide a recent reference point, and the sequential uplift anticipated in EBIT versus the prior quarter suggests some operational normalization even as year-over-year pressure persists. A crucial element is how realized prices align with contractual resets and how product mix evolves within the portfolio; shifts toward higher-value applications can mitigate unit margin pressure even if volumes remain constrained, while any promotions or price concessions could weigh on EBIT delivery. Cost containment, including logistics and energy efficiency measures, will be watched closely as a lever to stabilize gross margin through the quarter. Given the estimated small positive revenue change for the group, this segment’s contribution to consistency in absolute margin dollars becomes particularly important for meeting EBIT and EPS targets. The net profit outturn last quarter was robust on a sequential basis, but consensus this quarter embeds caution in profitability; that means investors will likely scrutinize evidence of improved contribution margins inside Bio Solutions as proof of execution. Any sign that pricing traction is holding without sacrificing volume would be viewed as supportive for the quarter’s EBIT delivery, while a shortfall in margin realization versus costs could cap upside on EPS even if revenue meets expectations.

Fine Chemicals: timing, order conversion, and incremental margin

Fine Chemicals generated 220.00 million Norwegian kroner in the last quarter and is often sensitive to order phasing and delivery timing, which can make it a swing factor around quarter-end closes. Consensus for the group sets a low bar on year-over-year profitability, so incremental contribution from this segment could be disproportionately impactful for meeting or exceeding EBIT expectations. Because Fine Chemicals revenues may be lumpy, a favorable shipment schedule or accelerated order conversion can push revenue recognition into the reported window and lift gross margin dollars, given the typically accretive nature of many specialized deliveries in this area. The interplay between working capital cycles and delivery timing matters here: efficient throughput, on-time qualification, and shipment execution can translate directly into reported revenue and EBIT mix. If the segment’s deliveries align with a high contribution margin profile, it can help offset broader margin headwinds that consensus already anticipates for the quarter. Conversely, any deferrals of high-margin batches would push downside risk into the current period and carry those revenues into subsequent quarters; this sensitivity underscores why close attention to backlog execution and operational cadence is warranted ahead of the print. Given that consensus embeds a 25.15% year-over-year decline in EBIT and a 41.02% decline in adjusted EPS for the group, even moderate outperformance from Fine Chemicals could narrow the gap to expectations, while under-delivery could reinforce the bearish skew implied by the EPS forecast. The key is that this segment’s incremental margin potential, when realized, can materially influence the quarter’s EPS trajectory relative to the relatively narrow revenue range that the market expects.

Stock price drivers this quarter: earnings power, margin realization, and FX

The first swing variable for the share price is the relationship between revenue delivery near 1.99 billion Norwegian kroner and the implied margin capture needed to achieve roughly 296.58 million Norwegian kroner of EBIT. With consensus embedding year-over-year pressure on both EBIT and EPS, the market is likely to react more to margin quality than to slight revenue deviation; a modest top-line beat without proportional margin expansion may not be rewarded if EPS remains constrained. Conversely, stable revenue with clearer evidence of margin stabilization could be sufficient for the shares to respond favorably if the results de-risk the second half. The second driver is the composition of margin between segments and SKUs, particularly whether higher-contribution volumes are realized in the quarter. Last quarter’s mix split shows a dominant contribution from Bio Solutions and meaningful weights from Bio Materials and Fine Chemicals; a move toward higher-value product mix can lift gross margin without large volume changes. Cost control will be another focal point: inflationary inputs, logistics, and process yields can either reinforce or erode the 21.35% gross margin reference point from the last quarter. Execution in plant utilization and throughput will be a determinant of incremental gross margin dollars and, by extension, EBIT and EPS outcomes. Foreign exchange is a third lever. With reporting in Norwegian kroner, movements versus key invoicing and cost currencies can influence both translation and underlying margin. If the Norwegian kroner strengthens against key revenue currencies during the quarter, translation could modestly dampen reported revenue, while weakness could provide a tailwind; hedging and natural offsets in the cost base will determine the net effect on gross margin. The market’s reaction function often prioritizes EPS sustainability; therefore, FX signals that improve or impair visibility into second-half earnings power are likely to influence the share reaction beyond the immediate quarter’s print. Beyond these primary drivers, working capital discipline will shape cash conversion and provide context for the quality of earnings. If receivables and inventories track efficiently against shipments, it will enhance confidence in reported profitability and reduce the risk of subsequent period adjustments. Capital allocation will be assessed through the lens of earnings visibility; steady investment aligned with efficiency improvements would be read as supporting future margin stability, while any indication of elevated maintenance intensity could temporarily weigh on free cash flow perceptions.

Analyst Opinions

Within the period from January 1, 2026 to July 9, 2026, published previews available in the public domain emphasize consensus modeling over directional calls, framing expectations as marginal revenue growth with compressed year-over-year profitability. Based on the accessible material, the ratio of bullish to bearish opinions skews toward a neutral or cautious stance, as we found references to consensus revenue of about 1.99 billion Norwegian kroner (+0.25% year over year) and adjusted EPS of approximately 1.59 (-41.02% year over year), with limited explicit buy or sell arguments accompanying those figures. Interpreting the tone and content, neutral/cautious comprises 100% of the identifiable commentary in the window, while explicit bullish or bearish calls were not observed; we therefore present the neutral/cautious majority view. Under the neutral/cautious lens, the core argument is that the quarter’s narrative is likely to hinge on margin proof points rather than top-line divergence. Forecasters see revenue near flat year over year, which places emphasis on whether pricing and mix are sufficient to defend gross margin against cost and operational variability. The projected decline in EBIT of 25.15% year over year and in adjusted EPS of 41.02% year over year encapsulates the risk that even with steady revenue, profitability may not fully recover to prior-year levels; this is the basis for a watchful stance rather than a bullish positioning. The presence of a modest revenue consensus range also implies that the bar for an upside surprise on sales is not high, but that the magnitude of an EPS beat would likely require stronger-than-expected margin capture or mix-favorable deliveries, potentially from segments where incremental margin per unit is higher. The neutral view also highlights the importance of sequential signals. Last quarter delivered a sequential rebound in net profit and a net profit margin of 9.08%, but EPS still declined year over year by 27.78%; neutral-leaning observers look for continuity in sequential improvement alongside any early signs that year-over-year comparisons are stabilizing. If the company demonstrates that gross margin can hold near or above the 21.35% reference while keeping opex contained, the pathway to revisiting profitability against a soft prior-year base in later quarters becomes clearer. However, given the embedded assumptions in the current quarter’s consensus—particularly the EPS compression—most neutral commentators prefer to see that stabilization evidenced in reported numbers before shifting tone. Finally, neutral/cautious commentary underscores three validation checks at the print: whether revenue lands near 1.99 billion Norwegian kroner within a tight variance; whether EBIT around 296.58 million Norwegian kroner is achieved without one-time support; and whether the adjusted EPS trajectory aligns with operational drivers rather than accounting asymmetries. Confirmation on these points would help narrow the gap between modeled profitability and realized performance. Conversely, if margin delivery falls short despite revenue performing to plan, the interpretation would be that top-line stability alone is insufficient to re-rate earnings power, keeping the stance neutral until clearer signs of margin durability appear for the remainder of the year.